FindTrial
Sign In

Levofolinate

DRUG8 trials

Sponsors

Eli Lilly and Company, Sanofi, Sumitomo Pharma Co., Ltd., National Cancer Center Hospital East, Ono Pharmaceutical Co. Ltd

Conditions

Colorectal Cancer MetastaticColorectal CarcinomaGastric CancerGastroesophageal Junction (GEJ) AdenocarcinomaMetastatic Colorectal CancerMetastatic Pancreatic CancerUnresectable Colorectal Cancer

Phase 1

A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)
CompletedNCT01286818
Eli Lilly and CompanyColorectal Carcinoma
Start: 2011-02-28End: 2012-03-31Updated: 2014-10-06
A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer
CompletedNCT02641873
Sumitomo Pharma Co., Ltd.Metastatic Colorectal Cancer
Start: 2015-12-31End: 2017-01-31Updated: 2022-04-12
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
Active, not recruitingNCT06532344
Ono Pharmaceutical Co. LtdMetastatic Pancreatic Cancer
Start: 2021-07-30End: 2026-12-31Updated: 2024-11-14
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
CompletedNCT06538207
Ono Pharmaceutical Co. LtdMetastatic Pancreatic Cancer
Start: 2021-01-13End: 2025-01-30Updated: 2025-02-06
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
Active, not recruitingNCT06540261
Ono Pharmaceutical Co. LtdUnresectable Colorectal Cancer
Start: 2021-09-23End: 2027-12-31Updated: 2024-09-19

Phase 2

A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
CompletedNCT01882868
SanofiColorectal Cancer Metastatic
Start: 2013-07-31End: 2015-08-31Updated: 2017-03-14
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer
Active, not recruitingNCT04745988
National Cancer Center Hospital EastGastric Cancer
Start: 2021-11-11End: 2027-08-31Target: 43Updated: 2024-11-15
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
RecruitingNCT07018570
National Cancer Center Hospital EastGastroesophageal Junction (GEJ) Adenocarcinoma
Start: 2025-07-24End: 2031-06-30Target: 26Updated: 2025-08-26

Related Papers

An open label phase 2 study of total neoadjuvant therapy (TNT) consisting of FLOT with pembrolizumab and short radiation for patients with locally advanced gastroesophageal junction adenocarcinoma (EPOC2301).
Journal of Clinical Oncology2026-01-10
An open-label phase 2 study of lenvatinib plus pembrolizumab in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001).
Journal of Clinical Oncology2022-01-191 citations
Exploration of potential prognostic biomarkers in aflibercept plus <scp>FOLFIRI</scp> in Japanese patients with metastatic colorectal cancer
Cancer Science2019-09-1415 citations
Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer.
2019-02-2232 citations
A phase II study of ziv-aflibercept (Z) + FOLFIRI in Japanese patients (pts) with metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology2017-02-013 citations
Exploratory evaluation of pharmacodynamic biomarkers and pharmacokinetics (PK) of ziv-aflibercept (Z) + FOLFIRI in a phase II study of Japanese patients (pts) with metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology2017-02-011 citations